LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq: OCUL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission (“SEC”).
Investors who purchased the Company’s shares between May 5, 2017 and July 6, 2017, inclusive (the “Class Period”), are encouraged to contact the firm before September 5, 2017, the lead plaintiff motion deadline.
If you are a shareholder who suffered a loss during the Class Period, click here to participate.
We also encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.goldberglawpc.com/, or by email at email@example.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Complaint alleges that during the Class Period, Ocular made false and/or misleading statements, and/or failed to disclose material information, about its business and operations. On May 5, 2017, the Company disclosed that the U.S. Food & Drug Administration (“FDA”) found minor issues at its manufacturing plant, but downplayed any concerns. On July 6, 2017, Seeking Alpha published an article alleging that Ocular’s management has been misleading investors about DEXTENZA manufacturing issues, including that more than half of lots manufactured by the Company contain bad product, and that these issues could imperil the approval of DEXTENZA by the FDA. Following this news, Ocular’s stock price dropped materially, which caused investors harm.
Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.